Chemomab Q2 net loss $2.8M; cash $67M; Phase 2 trials on track for 2022 data

Chemomab Therapeutics Ltd.

2022-Q2 EPS reported $0.02

Net loss $2.8M ($0.01 per share) vs $1.1M loss in Q2 2020; R&D expenses $1.3M (up from $0.8M).
Cash and equivalents $67M at June 30, 2021, up from $58.2M at March 31; runway to mid 2023.
CM-101 Phase 2a SPRING (PSC) and SPLASH (liver fibrosis) enrolling; data expected in 1H/2H 2022.
Expanded partnership with AGC Biologics to manufacture CM-101 for pivotal studies and launch readiness.
Plan to initiate Phase 2 trial in Systemic Sclerosis in Q1 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.